Morgan Stanley’s Vaccinex, Inc. Common Stock VCNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-4
| Closed | -$14 | – | 8175 |
|
|
2024
Q3 | $14 | Sell |
4
-1,109
| -100% | -$6.24K | ﹤0.01% | 7846 |
|
|
2024
Q2 | $7.22K | Hold |
1,113
| – | – | ﹤0.01% | 6766 |
|
|
2024
Q1 | $8.25K | Buy |
1,113
+1,112
| +111,200% | +$9.64K | ﹤0.01% | 6765 |
|
|
2023
Q4 | $13 | Hold |
1
| – | – | ﹤0.01% | 7746 |
|
|
2023
Q3 | $23 | Hold |
1
| – | – | ﹤0.01% | 7533 |
|
|
2023
Q2 | $107 | Hold |
1
| – | – | ﹤0.01% | 7491 |
|
|
2023
Q1 | $120 | Hold |
1
| – | – | ﹤0.01% | 7555 |
|
|
2022
Q4 | $193 | Sell |
1
-1
| -50% | -$124 | ﹤0.01% | 7647 |
|
|
2022
Q3 | $0 | Buy |
2
+1
| +100% | +$196 | ﹤0.01% | 7939 |
|
|
2022
Q2 | $0 | Sell |
1
-5
| -83% | -$1.28K | ﹤0.01% | 8040 |
|
|
2022
Q1 | $1K | Buy |
6
+5
| +500% | +$1.38K | ﹤0.01% | 7884 |
|
|
2021
Q4 | $0 | Sell |
1
-1
| -50% | -$361 | ﹤0.01% | 8152 |
|
|
2021
Q3 | $1K | Hold |
2
| – | – | ﹤0.01% | 7818 |
|
|
2021
Q2 | $1K | Hold |
2
| – | – | ﹤0.01% | 7644 |
|
|
2021
Q1 | $1K | Buy |
2
+1
| +100% | +$643 | ﹤0.01% | 7394 |
|
|
2020
Q4 | $1K | Sell |
1
-2
| -67% | -$837 | ﹤0.01% | 6984 |
|
|
2020
Q3 | $1K | Buy |
3
+2
| +200% | +$2.18K | ﹤0.01% | 6682 |
|
|
2020
Q2 | $1K | Hold |
1
| – | – | ﹤0.01% | 6540 |
|
|
2020
Q1 | $1K | Hold |
1
| – | – | ﹤0.01% | 6503 |
|
|
2019
Q4 | $1K | Buy |
+1
| New | +$1.13K | ﹤0.01% | 6601 |
|
|
2019
Q3 | – | Hold |
0
| – | – | – | 6791 |
|
|
2019
Q2 | – | Hold |
0
| – | – | – | 6777 |
|
|
2019
Q1 | – | Hold |
0
| – | – | – | 6739 |
|
|
2018
Q4 | – | Sell |
-12
| Closed | -$14.7K | – | 6766 |
|
|
2018
Q3 | $19K | Buy |
+12
| New | +$24.8K | ﹤0.01% | 6160 |
|
Other funds holding VCNX
Morgan Stanley's VCNX Position: Q4 2024 in Review
Morgan Stanley sold out of Vaccinex, Inc. Common Stock (VCNX) in Q4 2024, closing a stake of 4 shares — an estimated $14 sold.
Morgan Stanley first reported a position in VCNX in Q3 2018 and held it in 21 quarters. The position peaked at $19K in Q3 2018. 1 fund tracked by Wall St. Rank holds VCNX as of Q4 2024.
- Morgan Stanley reported no remaining Vaccinex, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- Morgan Stanley sold 4 Vaccinex, Inc. Common Stock shares in Q4 2024, an estimated $14.
- Morgan Stanley first reported a position in Vaccinex, Inc. Common Stock in Q3 2018 and held it in 21 quarters.
- Morgan Stanley's Vaccinex, Inc. Common Stock position peaked at $19K in Q3 2018.
- 1 fund tracked by Wall St. Rank held Vaccinex, Inc. Common Stock as of Q4 2024.
Based on Morgan Stanley's 13F filing for Q4 2024, filed 14 Feb 2025.